마우스 모델 시장 : 모델 유형, 연령층, 조달 형태, 질환 유도법, 용도, 최종 사용자별 예측(2026-2032년)

The Mice Model Market is projected to grow by USD 3.11 billion at a CAGR of 8.66% by 2032.

The mice model market remains a foundational pillar of preclinical research because laboratory mouse models provide genetically tractable, reproducible, and biologically relevant systems for studying human disease. Mouse and human biology share extensive genetic and physiological similarities, supporting continued use in oncology, immunology, metabolic disease, neuroscience, infectious disease, toxicology, and vaccine research.

For preclinical model providers and contract research organizations, demand is increasingly concentrated around humanized mice, transgenic mice, knockout mice, patient-derived xenograft models, germ-free models, immunodeficient strains, and disease-specific in vivo platforms. Buyers are prioritizing validated phenotypes, reproducible background strains, strong animal welfare compliance, defined microbial status, and faster study turnaround as drug developers seek higher-confidence translational evidence before clinical investment.

Transformative Shifts in the Mice Model Landscape

The mice model landscape is shifting from standardized colony supply toward specialized, data-rich preclinical solutions. CRISPR-Cas9 genome editing has accelerated the creation of targeted knockout, knock-in, conditional, and reporter mouse models, while humanized immune system models and patient-derived xenograft platforms are expanding their role in oncology, immuno-oncology, autoimmune disease, and infectious disease testing.

Regulatory and ethical expectations are also reshaping purchasing behavior. The 3Rs principles of replacement, reduction, and refinement, ARRIVE reporting guidelines, and institutional animal care standards are pushing providers to document welfare practices, genetic integrity, microbial status, study reproducibility, and endpoint justification. This transformation favors partners that combine scientific customization with transparent quality systems and robust in vivo research governance.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical enabler across the mice model value chain. AI-supported image analysis, automated behavioral tracking, digital pathology, high-content phenotyping, and longitudinal monitoring help reduce observer bias and extract more endpoints from each study, supporting the reduction principle within the 3Rs framework.

For model providers, AI also improves colony management, breeding forecasts, genotype-phenotype interpretation, and study design optimization. Predictive analytics can help identify appropriate cohort structures, reduce failed breeding cycles, flag welfare anomalies, and detect outliers earlier. The strongest commercial advantage will come from integrating AI with validated wet-lab workflows, controlled experimental design, and expert biological interpretation rather than positioning algorithms as substitutes for translational evidence.

Key Regional Insights for Mice Model Providers

North America remains a leading hub for mice model services due to its dense concentration of biopharmaceutical R&D, NIH-funded academic research, advanced vivarium infrastructure, and established contract research capabilities. Europe continues to emphasize welfare-driven innovation through EU Directive 2010/63/EU, rigorous ethical review, and broad adoption of the 3Rs, while maintaining strong demand for genetically engineered mouse models, oncology models, immunology platforms, and pharmacology studies.

Asia-Pacific is expanding as China, Japan, South Korea, India, Australia, and Singapore invest in translational medicine, genome editing, oncology research infrastructure, and regulated preclinical capabilities. Latin America is led by Brazil and Mexico in biomedical research capacity, infectious disease studies, and academic animal research programs, while the Middle East is building biomedical clusters, precision medicine initiatives, and hospital-linked research programs across the GCC. Africa remains earlier stage but is gaining relevance through infectious disease research, public health collaborations, vaccine-related studies, and university-led laboratory animal programs that support region-specific biomedical priorities.

Key Group Insights Across Research Blocs

ASEAN markets are increasingly important for preclinical outsourcing as Singapore, Thailand, Malaysia, Vietnam, Indonesia, and the Philippines strengthen biomedical research ecosystems, laboratory capacity, and multinational academic collaborations. GCC countries are investing in precision medicine, academic medical centers, genomics programs, and healthcare innovation strategies, creating selective demand for high-quality animal research partnerships, imported specialized strains, and compliant preclinical testing support.

The European Union sets a global benchmark for animal welfare governance, data transparency, harmonized compliance, and structured ethical assessment under Directive 2010/63/EU. BRICS countries, especially China, India, and Brazil, are expanding domestic capabilities in genetic engineering, disease modeling, biomanufacturing-linked research, and translational medicine. G7 markets remain premium buyers of validated mice models due to mature biopharmaceutical pipelines, strong academic funding, and advanced regulatory expectations, while NATO-aligned countries benefit from biomedical security, infectious disease preparedness, trauma research, and defense-related medical research priorities that sustain demand for reliable in vivo models.

Key Country Insights in the Mice Model Market

The United States is the largest strategic market for advanced mice model services, supported by NIH funding, biopharma pipelines, specialized vivarium infrastructure, and mature CRO capacity. Canada contributes strong academic research, translational medicine networks, and ethical oversight, while Mexico supports regional research, manufacturing-linked life sciences activity, and growing clinical and biomedical collaboration. Brazil leads Latin America through major universities, biomedical institutes, infectious disease expertise, and established public research systems.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain strong demand for transgenic mice, knockout models, oncology models, and disease-specific platforms under strict animal welfare systems, while Russia retains scientific capacity in biomedical research despite geopolitical and collaboration constraints. China is scaling domestic model production, CRISPR capabilities, humanized mouse platforms, and oncology research capacity; India is expanding translational research, vaccine development, and pharmacology capabilities; Japan and South Korea remain advanced innovation hubs for regenerative medicine, immunology, oncology, and precision research; and Australia supports immunology, oncology, neuroscience, and infectious disease research through well-regulated institutions and strong university-led biomedical programs.

Actionable Recommendations for Industry Leaders

Industry vendors should prioritize model validation, genetic authentication, microbial and microbiome control, environmental standardization, and transparent study documentation as core differentiators. Providers that can demonstrate reproducibility across sites, ethical compliance, robust quality assurance, and clinically relevant endpoints will be better positioned for high-value partnerships with pharmaceutical, biotechnology, academic, and government research clients.

Commercial teams should invest in humanized models, patient-derived xenograft libraries, CRISPR-enabled custom model generation, germ-free and gnotobiotic capabilities, and AI-enhanced phenotyping. Partnerships with academic disease centers, biobanks, and translational research networks can strengthen scientific credibility. Vendors should also communicate 3Rs-aligned study design, because buyers increasingly view welfare, data integrity, operational efficiency, and regulatory readiness as linked performance indicators in preclinical research outsourcing.

Research Methodology

This executive summary is built from verified industry knowledge across preclinical research, laboratory animal science, genome engineering, regulatory guidance, biomedical R&D trends, and translational medicine practices. The analysis reflects established frameworks including the 3Rs principles, ARRIVE reporting guidance, EU animal research rules, institutional animal care and use requirements, and recognized practices in genetically engineered, immunodeficient, germ-free, and humanized mouse model development.

Market interpretation focuses on evidence-backed demand drivers rather than speculative claims. Regional, group, and country insights are assessed through observable research capacity, biopharmaceutical activity, regulatory maturity, academic infrastructure, public health priorities, and translational medicine investment. Conclusion

The mice model market is evolving from a commodity animal supply segment into a precision preclinical research ecosystem. Industry direction is being shaped by humanized models, CRISPR-edited strains, patient-derived xenograft platforms, oncology and immunology applications, infectious disease research, AI-enabled phenotyping, and rising expectations for reproducible, welfare-conscious science.

For providers and CROs, competitive advantage will depend on scientific depth, operational quality, data transparency, animal welfare alignment, and the ability to comply with global research standards. Organizations that integrate ethical animal research with advanced disease modeling, controlled study design, and digital analytics will be best positioned to serve the next generation of translational medicine.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Mice Model Market, by Model Type

• 7.1. Genetically Engineered Mice Models
  • 7.1.1. Conditional Knockout Models
  • 7.1.2. Humanized Mice Models
  • 7.1.3. Knockout Models
  • 7.1.4. Transgenic Models
• 7.2. Inbred Mice Models
• 7.3. Outbred Mice Models

8. Mice Model Market, by Age Cohort

• 8.1. Embryonic
• 8.2. Neonatal
• 8.3. Juvenile
• 8.4. Adult
• 8.5. Aged

9. Mice Model Market, by Procurement Format

• 9.1. Live Animals
  • 9.1.1. Experimental Cohorts
  • 9.1.2. Breeding Stock
  • 9.1.3. Timed-Pregnant Females
• 9.2. Cryopreserved Materials
  • 9.2.1. Embryos
  • 9.2.2. Sperm

10. Mice Model Market, by Disease Induction Method

• 10.1. Spontaneous Models
• 10.2. Chemically Induced Models
• 10.3. Diet-Induced Models
• 10.4. Surgically Induced Models
• 10.5. Infection-Induced Models

11. Mice Model Market, by Application

• 11.1. Behavioral Studies
• 11.2. Cardiovascular Diseases
• 11.3. Drug Discovery & Toxicology
• 11.4. Genetic Disease Research
• 11.5. Immunology
• 11.6. Infectious Diseases
• 11.7. Metabolic Disorders
• 11.8. Neurology & Neurodegenerative Diseases
• 11.9. Oncology Research

12. Mice Model Market, by End User

• 12.1. Academic & Research Institutions
• 12.2. Contract Research Organizations (CROs)
• 12.3. Hospitals & Diagnostic Centers
• 12.4. Pharmaceutical & Biotechnology Companies

13. Mice Model Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Mice Model Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Mice Model Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Applied StemCell, Inc.
• 17.2. Aragen Life Sciences Ltd.
• 17.3. Biocytogen Boston Corporation
• 17.4. Charles River Laboratories International, Inc.
• 17.5. Creative Biolabs
• 17.6. Crown Bioscience by JSR Life Sciences, LLC
• 17.7. Cyagen Biosciences Suzhou Inc.
• 17.8. Cyagen US Inc. by PolyGene AG
• 17.9. Envigo by Inotiv, Inc.
• 17.10. GemPharmatech Co., Ltd.
• 17.11. GenOway
• 17.12. Harbour BioMed
• 17.13. Hera BioLabs, Inc.
• 17.14. inGenious Targeting Laboratory, Inc.
• 17.15. Janvier Labs
• 17.16. Marshall BioResources
• 17.17. MD Biosciences
• 17.18. Mirimus, Inc.
• 17.19. Ozgene Pty Ltd.
• 17.20. PhoenixBio Co., Ltd.
• 17.21. Shanghai Model Organisms Center, Inc.
• 17.22. Taconic Biosciences, Inc.
• 17.23. The Jackson Laboratory
• 17.24. TransCure bioServices
• 17.25. Translational Drug Development, LLC
• 17.26. Urosphere SAS
• 17.27. Vitalstar Biotechnology Co., Ltd.
• 17.28. XenOPAT SL by Bellvitge Biomedical Research Institute